On a Vertex call (my memory is not that good but I believe it was at the SIG conference) they pointed out some reasons why they believed Boceprevir results were cherry picked (my words) because of the way they prescreened.
[Removed entry for HCV-796, which is now officially dead. (I had previously listed it in the bottommost rung on the ladder.]
The following paragraphs are in descending order of likelihood of success. (Paragraphs 6 and 8 are “catchall” groupings that do not explicitly mention all of the applicable drug candidates within the grouping.)
3. Locteron (OctoPlus/Biolex; phase-2), a long-acting interferon made in transgenic plants: #msg-26612906.
4. Various oral agents in phase-1 or phase-2 trials that use an established MoA. These include TMC435350 (Medivir/JNJ; entering phase-2): #msg-24754963; R7128 (VRUS/Roche; phase-1b): #msg-25785397; and R1626 (Roche; phase-2): #msg-24230355.
5. The “other” interferons: Albuferon (HGSI/NVS; dose reduced in phase-3): #msg-26199740; IFN-alpha-XL (FLML; phase-1): #msg-24008801; and IFN-Lambda (ZGEN; phase-1): #msg-16610804. I’m excluding MAXY’s Maxy-alpha, which has been on life support since Roche dropped the program: #msg-24801678.
6. Miscellaneous very-early-stage compounds that use an established MoA; e.g. IDX184 from IDIX: #msg-25802238, #msg-25836105.
7. GS9190 (GILD; phase-1), which has caused QT-prolongation: #msg-24268443.
8. Miscellaneous early-stage compounds that use novel MoA’s; e.g. Sirna-034, now owned by MRK: #msg-12665661.
Market Data 
Markets 
AI
